Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of TDF/FTC PrEP in Transgender Women on Hormone Therapy
NCT03270969Phase 1Completed
- Sponsor
- University of Nebraska
- Start
- Jan 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenofovir disoproxil fumarate and emtricitabine in human immunodeficiency virus infection (HIV), sponsored by University of Nebraska. Primary endpoint: Tenofovir plasma exposure (AUC) at 14 days. Started Jan 2018; status: completed.
02
Drugs
tenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03270969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03270969.